Medtronic (NYSE: MDT) has named Jorie Soskin as its new VP and GM of its TAVR and Congenital Heart businesses.

"Medtronic’s Aurora EV-ICD to challenge Boston Scientific’s S-ICD market leadership" was originally created and published by ...

Medtronic, a global developer and manufacturer of medical devices for chronic diseases, is now a $111 billion (by market cap) ...

First double-blind randomised trial of its kind finds widely used ablation procedure significantly reduces atrial fibrillation burden and substantially improves symptoms and quality of life compared ...

In April, Medtronic obtained FDA approval for another new product, Inceptiv, a spinal cord stimulator for treating chronic pain. The device can automatically adjust the therapy — a unique feature — to ...

Particularly, the company’s AFib, Structural Heart ... FDA’s approval for the treatment of symptomatic severe aortic stenosis. In the fiscal first quarter, Medtronic stock lost 0.1% in ...

Medtronic faced challenges ... Along these lines, it is the market leader in heart devices, insulin pumps, neuromodulators, spinal products, acute care & monitoring, etc. This scale and leadership ...

The Ireland-based company also eyes growth across segments such as diabetes and devices for heart disease-focused surgeries. Medtronic also remains "on the hunt" for the right tuck-in deals.

A scientific statement has been published by the American Heart Association regarding renal denervation for the treatment of hypertension.

Bridgewater Associates is loading up on shares of ExxonMobil, Medtronic, and Microsoft. Here's what you need to know.

Medtronic delivered a strong first-quarter ... including the effect of an aging population and increased spending on the treatment of chronic diseases, support a positive long-term outlook for ...